Try our beta test site
64716 studies found for:    "Molecular Mechanisms of Pharmacological Action"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)
Conditions: Dyslipidemias;   Hypertension;   Vasodilation;   Oxidative Stress;   Inflammation
Interventions: Dietary Supplement: Salvia miltiorrhiza extract;   Dietary Supplement: Placebo
2 Terminated The Intravascular Cooling in the Treatment of Stroke 2/3 Trial
Condition: Stroke, Acute
Interventions: Device: hypothermia;   Other: Group1: IV t-PA and normothermia
3 Completed Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo
Condition: Infantile Hemangioma
Interventions: Drug: propranolol gel;   Drug: Placebo
4 Recruiting PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: [68Ga]RM2;   Procedure: PET/CT
5 Completed Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: GS-9857;   Drug: Placebo to match GS-9857;   Drug: SOF/GS-5816
6 Active, not recruiting A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions: Drug: Bosutinib;   Drug: Imatinib
7 Completed
Has Results
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-0893;   Drug: Metformin;   Drug: Placebo
8 Suspended Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
Condition: Acute Ischemic Stroke
Intervention:
9 Completed
Has Results
Tecemotide (L-BLP25) in Rectal Cancer
Condition: Rectal Cancer
Interventions: Biological: Tecemotide (L-BLP25);   Drug: cyclophosphamide (CPA);   Other: Chemoradiotherapy
10 Completed A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small Cell-Lung;   Lung Neoplasms;   Lung Cancer;   Respiratory Tract Neoplasms
Interventions: Biological: AV-299 + gefitinib;   Drug: Gefitinib
11 Completed Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Condition: Thoracic Neoplasms
Interventions: Drug: erlotinib;   Drug: gefitinib
12 Completed Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex
Condition: Neuromuscular Blockade
Interventions: Drug: Magnesium Sulfate;   Drug: Saline
13 Withdrawn Melatonin Supplementation to Improve Sleep in Patients With Heart Failure
Conditions: Heart Failure;   Sleep Disorders
Interventions: Drug: melatonin;   Drug: placebo
14 Recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
15 Recruiting Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Condition: Primary IgA Nephropathy
Interventions: Drug: Hydroxychloroquine Sulfate;   Drug: Valsartan
16 Active, not recruiting Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Condition: Polycythemia Vera
Intervention:
17 Active, not recruiting Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer
Interventions: Drug: Patritumab;   Drug: erlotinib:;   Drug: Placebo
18 Completed Tranexamic Acid in Reverse Total Shoulder Arthroplasty
Conditions: Shoulder Joint Disease;   Complications; Arthroplasty;   Intraoperative Complications;   Blood Loss, Surgical
Interventions: Drug: Tranexamic Acid;   Drug: Placebo
19 Completed
Has Results
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C Virus
Interventions: Drug: SOF;   Drug: RBV
20 Completed
Has Results
Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)
Condition: Heartburn
Interventions: Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg;   Drug: Omeprazole 20 mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.